Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith Wheatley

Showing results (131-140 of 145) with videos related to

Pageof 15
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2017
Outcome of Azacitidine Therapy in Acute Myeloid Leukemia Is not Improved by Concurrent Vorinostat Therapy but Is Predicted by a Diagnostic Molecular SignatureCharles F Craddock, Aimee E Houlton, Lynn Swun Quek, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 27, 2021
Dose-Adjusted Etoposide, Doxorubicin, and Cyclophosphamide With Vincristine and Prednisone Plus Rituximab Therapy in Children and Adolescents With Primary Mediastinal B-Cell Lymphoma: A Multicenter Phase II TrialG A Amos Burke, Veronique Minard-Colin, Anne Aupérin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 4, 2022
Reply to R. Lakhotia et alG A Amos Burke, Veronique Minard-Colin, Anne Aupérin, et al.
The British Journal of Dermatology|January 6, 2022
Topical treatment of actinic keratoses in organ transplant recipients: a feasibility study for SPOT (Squamous cell carcinoma Prevention in Organ transplant recipients using Topical treatments)Zeeshaan-Ul Hasan, Ikhlaaq Ahmed, Rubeta N Matin, et al.
Lancet (London, England)|December 6, 2005
Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective studyPeter J Campbell, Linda M Scott, Georgina Buck, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 29, 2020
Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid LeukemiaCharles Craddock, Aimee Jackson, Justin Loke, et al.
Frontiers in Oncology|February 15, 2024
PARC: a phase I/II study evaluating the safety and activity of pegylated recombinant human arginase BCT-100 in relapsed/refractory cancers of children and young adultsNicola Fenwick, Rebekah Weston, Keith Wheatley, et al.
Cancers|March 13, 2024
Frontline and Relapsed Rhabdomyosarcoma (FaR-RMS) Clinical Trial: A Report from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG)Julia Chisholm, Henry Mandeville, Madeleine Adams, et al.
Cancers|October 16, 2024
Correction: Chisholm et al. Frontline and Relapsed Rhabdomyosarcoma (FaR-RMS) Clinical Trial: A Report from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG). <i>Cancers</i> 2024, <i>16</i>, 998Julia Chisholm, Henry Mandeville, Madeleine Adams, et al.
Health Technology Assessment (Winchester, England)|September 26, 2022
Plasma exchange and glucocorticoids to delay death or end-stage renal disease in anti-neutrophil cytoplasm antibody-associated vasculitis: PEXIVAS non-inferiority factorial RCTDavid Jayne, Michael Walsh, Peter A Merkel, et al.
Pageof 15

Showing results (131-140 of 145) with videos related to

Sort By:
Pageof 15
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2017
Outcome of Azacitidine Therapy in Acute Myeloid Leukemia Is not Improved by Concurrent Vorinostat Therapy but Is Predicted by a Diagnostic Molecular SignatureCharles F Craddock, Aimee E Houlton, Lynn Swun Quek, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 27, 2021
Dose-Adjusted Etoposide, Doxorubicin, and Cyclophosphamide With Vincristine and Prednisone Plus Rituximab Therapy in Children and Adolescents With Primary Mediastinal B-Cell Lymphoma: A Multicenter Phase II TrialG A Amos Burke, Veronique Minard-Colin, Anne Aupérin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 4, 2022
Reply to R. Lakhotia et alG A Amos Burke, Veronique Minard-Colin, Anne Aupérin, et al.
The British Journal of Dermatology|January 6, 2022
Topical treatment of actinic keratoses in organ transplant recipients: a feasibility study for SPOT (Squamous cell carcinoma Prevention in Organ transplant recipients using Topical treatments)Zeeshaan-Ul Hasan, Ikhlaaq Ahmed, Rubeta N Matin, et al.
Lancet (London, England)|December 6, 2005
Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective studyPeter J Campbell, Linda M Scott, Georgina Buck, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 29, 2020
Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid LeukemiaCharles Craddock, Aimee Jackson, Justin Loke, et al.
Frontiers in Oncology|February 15, 2024
PARC: a phase I/II study evaluating the safety and activity of pegylated recombinant human arginase BCT-100 in relapsed/refractory cancers of children and young adultsNicola Fenwick, Rebekah Weston, Keith Wheatley, et al.
Cancers|March 13, 2024
Frontline and Relapsed Rhabdomyosarcoma (FaR-RMS) Clinical Trial: A Report from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG)Julia Chisholm, Henry Mandeville, Madeleine Adams, et al.
Cancers|October 16, 2024
Correction: Chisholm et al. Frontline and Relapsed Rhabdomyosarcoma (FaR-RMS) Clinical Trial: A Report from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG). <i>Cancers</i> 2024, <i>16</i>, 998Julia Chisholm, Henry Mandeville, Madeleine Adams, et al.
Health Technology Assessment (Winchester, England)|September 26, 2022
Plasma exchange and glucocorticoids to delay death or end-stage renal disease in anti-neutrophil cytoplasm antibody-associated vasculitis: PEXIVAS non-inferiority factorial RCTDavid Jayne, Michael Walsh, Peter A Merkel, et al.
Pageof 15